{"product_id":"injectable-lgd4033-250mg-vial","title":"Injectable LGD4033 250mg vial","description":"\u003cp\u003e\u003cspan\u003e\u003cstrong\u003e\u003cstrong data-start=\"377\" data-end=\"392\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e                                           \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"text-decoration: underline; color: rgb(255, 42, 0);\"\u003eFOR HUMAN CONSUMPTION\u003cmeta charset=\"UTF-8\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"564\" data-start=\"54\"\u003e\u003cstrong\u003eLGD-4033\u003c\/strong\u003e is a non-steroidal \u003cstrong data-end=\"170\" data-start=\"122\"\u003eselective androgen receptor modulator (SARM)\u003c\/strong\u003e designed to produce \u003cstrong data-end=\"230\" data-start=\"191\"\u003eanabolic effects in muscle and bone\u003c\/strong\u003e with comparatively \u003cstrong data-end=\"287\" data-start=\"250\"\u003eless stimulation of prostate\/skin\u003c\/strong\u003e than testosterone. It binds the \u003cstrong data-end=\"346\" data-start=\"320\"\u003eandrogen receptor (AR)\u003c\/strong\u003e, recruits co-activators in muscle\/bone, and avoids \u003cstrong data-end=\"415\" data-start=\"398\"\u003e5-α reduction\u003c\/strong\u003e and \u003cstrong data-end=\"437\" data-start=\"420\"\u003earomatization\u003c\/strong\u003e. LGD-4033 is \u003cstrong data-end=\"475\" data-start=\"451\"\u003enot FDA\/EMA-approved\u003c\/strong\u003e; it remains an investigational agent and is \u003cstrong data-end=\"542\" data-start=\"520\"\u003eprohibited by WADA\u003c\/strong\u003e as an anabolic agent.\u003c\/p\u003e\n\u003chr data-end=\"569\" data-start=\"566\"\u003e\n\u003ch3 data-end=\"630\" data-start=\"571\"\u003eAdditional Benefits of LGD-4033 Now Under Investigation\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"2790\" data-start=\"632\"\u003e\n\u003cthead data-end=\"660\" data-start=\"632\"\u003e\n\u003ctr data-end=\"660\" data-start=\"632\"\u003e\n\u003cth data-col-size=\"md\" data-end=\"642\" data-start=\"632\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-col-size=\"xl\" data-end=\"660\" data-start=\"642\"\u003eKey take-aways\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"2790\" data-start=\"671\"\u003e\n\u003ctr data-end=\"990\" data-start=\"671\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"720\" data-start=\"671\"\u003e\u003cstrong data-end=\"719\" data-start=\"673\"\u003e1 Lean-mass accrual in humans (short term)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"990\" data-start=\"720\"\u003eIn a 21-day, randomized, placebo-controlled trial in healthy men, \u003cstrong data-end=\"847\" data-start=\"788\"\u003edose-dependent increases in fat-free mass (~0.6–1.5 kg)\u003c\/strong\u003e occurred without major fluid retention; strength\/power showed favorable trends. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Journal of Gerontology: Medical Sciences; JCEM\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1240\" data-start=\"991\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1022\" data-start=\"991\"\u003e\u003cstrong data-end=\"1021\" data-start=\"993\"\u003e2 Functional performance\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1240\" data-start=\"1022\"\u003eImprovements in \u003cstrong data-end=\"1062\" data-start=\"1040\"\u003eleg-press strength\u003c\/strong\u003e and \u003cstrong data-end=\"1088\" data-start=\"1067\"\u003estair-climb power\u003c\/strong\u003e have been reported in small studies—consistent with anabolic signaling translating to function. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Medicine \u0026amp; Science in Sports \u0026amp; Exercise\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1509\" data-start=\"1241\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1274\" data-start=\"1241\"\u003e\u003cstrong data-end=\"1273\" data-start=\"1243\"\u003e3 Anti-catabolic potential\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1509\" data-start=\"1274\"\u003eIn preclinical atrophy models (castration, hind-limb unloading), LGD-4033 \u003cstrong data-end=\"1374\" data-start=\"1350\"\u003epreserves muscle CSA\u003c\/strong\u003e and \u003cstrong data-end=\"1432\" data-start=\"1379\"\u003ereduces ubiquitin-ligase (MAFbx\/MuRF1) expression\u003c\/strong\u003e. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;FASEB Journal; American Journal of Physiology–Endocrinology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1742\" data-start=\"1510\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1540\" data-start=\"1510\"\u003e\u003cstrong data-end=\"1539\" data-start=\"1512\"\u003e4 Bone-anabolic signals\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1742\" data-start=\"1540\"\u003eIn rodent osteopenia, LGD-class SARMs \u003cstrong data-end=\"1623\" data-start=\"1580\"\u003eincrease BMD and biomechanical strength\u003c\/strong\u003e, with \u003cstrong data-end=\"1649\" data-start=\"1630\"\u003eosteocalcin\/ALP\u003c\/strong\u003e rises and limited prostate stimulation. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Journal of Bone and Mineral Research\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1975\" data-start=\"1743\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1799\" data-start=\"1743\"\u003e\u003cstrong data-end=\"1798\" data-start=\"1745\"\u003e5 Recovery after immobilization\/illness (concept)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1975\" data-start=\"1799\"\u003eEarly translational work explores \u003cstrong data-end=\"1877\" data-start=\"1835\"\u003epost-fracture and post-hospitalization\u003c\/strong\u003e lean-mass restoration with exercise\/rehab. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Geriatrics \u0026amp; Gerontology International\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2179\" data-start=\"1976\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2008\" data-start=\"1976\"\u003e\u003cstrong data-end=\"2007\" data-start=\"1978\"\u003e6 Erythropoiesis (modest)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2179\" data-start=\"2008\"\u003eAndrogen-axis engagement may \u003cstrong data-end=\"2079\" data-start=\"2039\"\u003eslightly raise hemoglobin\/hematocrit\u003c\/strong\u003e, below testosterone’s magnitude—requires monitoring in at-risk patients. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Hematology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2373\" data-start=\"2180\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2205\" data-start=\"2180\"\u003e\u003cstrong data-end=\"2204\" data-start=\"2182\"\u003e7 Oral convenience\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2373\" data-start=\"2205\"\u003e\n\u003cstrong data-end=\"2233\" data-start=\"2207\"\u003eOnce-daily oral dosing\u003c\/strong\u003e with a long half-life supports adherence in trials compared with injectable anabolics. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Clinical Pharmacology \u0026amp; Therapeutics\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2601\" data-start=\"2374\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2401\" data-start=\"2374\"\u003e\u003cstrong data-end=\"2400\" data-start=\"2376\"\u003e8 Tissue selectivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2601\" data-start=\"2401\"\u003eNon-steroidal AR binding yields \u003cstrong data-end=\"2475\" data-start=\"2435\"\u003elower sebaceous\/prostate stimulation\u003c\/strong\u003e per unit anabolic effect versus 17-α-alkylated androgens. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Journal of Pharmacology \u0026amp; Experimental Therapeutics\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2790\" data-start=\"2602\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2647\" data-start=\"2602\"\u003e\u003cstrong data-end=\"2646\" data-start=\"2604\"\u003e9 Combination with resistance training\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2790\" data-start=\"2647\"\u003ePreliminary data suggest \u003cstrong data-end=\"2692\" data-start=\"2674\"\u003eadditive gains\u003c\/strong\u003e when paired with structured training and adequate protein intake. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Sports Medicine\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"2795\" data-start=\"2792\"\u003e\n\u003ch2 data-end=\"2832\" data-start=\"2797\"\u003e2. Molecular Mechanism of Action\u003c\/h2\u003e\n\u003ch3 data-end=\"2869\" data-start=\"2834\"\u003e2.1 Receptor Pharmacodynamics\u003c\/h3\u003e\n\u003cp data-end=\"3219\" data-start=\"2870\"\u003eLGD-4033 binds \u003cstrong data-end=\"2891\" data-start=\"2885\"\u003eAR\u003c\/strong\u003e → nuclear translocation → \u003cstrong data-end=\"2946\" data-start=\"2918\"\u003eARE-driven transcription\u003c\/strong\u003e. In muscle, it up-regulates \u003cstrong data-end=\"2989\" data-start=\"2975\"\u003emTOR\/IGF-1\u003c\/strong\u003enetworks and down-regulates \u003cstrong data-end=\"3031\" data-start=\"3018\"\u003eatrogenes\u003c\/strong\u003e; in bone, it enhances \u003cstrong data-end=\"3077\" data-start=\"3054\"\u003eosteoblast activity\u003c\/strong\u003e and may suppress \u003cstrong data-end=\"3117\" data-start=\"3095\"\u003eosteoclastogenesis\u003c\/strong\u003eindirectly. Lack of aromatization\/5-α reduction underlies its \u003cstrong data-end=\"3202\" data-start=\"3180\"\u003etissue selectivity\u003c\/strong\u003e vs testosterone.\u003c\/p\u003e\n\u003ch3 data-end=\"3248\" data-start=\"3221\"\u003e2.2 Down-stream Biology\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"3599\" data-start=\"3250\"\u003e\n\u003cthead data-end=\"3292\" data-start=\"3250\"\u003e\n\u003ctr data-end=\"3292\" data-start=\"3250\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3260\" data-start=\"3250\"\u003ePathway\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"3281\" data-start=\"3260\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3292\" data-start=\"3281\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"3599\" data-start=\"3307\"\u003e\n\u003ctr data-end=\"3386\" data-start=\"3307\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3323\" data-start=\"3307\"\u003eAR → mTOR\/S6K\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3367\" data-start=\"3323\"\u003e↑ protein synthesis, myofiber hypertrophy\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3386\" data-start=\"3367\"\u003eSkeletal muscle\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3454\" data-start=\"3387\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3416\" data-start=\"3387\"\u003eAR → Wnt\/β-catenin\/Osterix\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3446\" data-start=\"3416\"\u003e↑ osteoblastogenesis, ↑ BMD\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3454\" data-start=\"3446\"\u003eBone\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3532\" data-start=\"3455\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3482\" data-start=\"3455\"\u003e↓ FoxO\/ubiquitin ligases\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3512\" data-start=\"3482\"\u003e↓ proteolysis (MAFbx\/MuRF1)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3532\" data-start=\"3512\"\u003eCatabolic states\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3599\" data-start=\"3533\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3563\" data-start=\"3533\"\u003eMyostatin\/activin crosstalk\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3589\" data-start=\"3563\"\u003eFavors anabolic balance\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3599\" data-start=\"3589\"\u003eMuscle\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"3604\" data-start=\"3601\"\u003e\n\u003ch2 data-end=\"3628\" data-start=\"3606\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cul data-end=\"4088\" data-start=\"3630\"\u003e\n\u003cli data-end=\"3650\" data-start=\"3630\"\u003e\n\u003cp data-end=\"3650\" data-start=\"3632\"\u003e\u003cstrong data-end=\"3642\" data-start=\"3632\"\u003eRoute:\u003c\/strong\u003e Oral.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3743\" data-start=\"3651\"\u003e\n\u003cp data-end=\"3743\" data-start=\"3653\"\u003e\u003cstrong data-end=\"3667\" data-start=\"3653\"\u003eHalf-life:\u003c\/strong\u003e \u003cstrong data-end=\"3680\" data-start=\"3668\"\u003e~24–36 h\u003c\/strong\u003e, allowing \u003cstrong data-end=\"3705\" data-start=\"3691\"\u003eonce-daily\u003c\/strong\u003e dosing; \u003cstrong data-end=\"3740\" data-start=\"3714\"\u003esteady state ~5–7 days\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3831\" data-start=\"3744\"\u003e\n\u003cp data-end=\"3831\" data-start=\"3746\"\u003e\u003cstrong data-end=\"3773\" data-start=\"3746\"\u003eAbsorption\/food effect:\u003c\/strong\u003e Good oral bioavailability; minor food effects reported.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3917\" data-start=\"3832\"\u003e\n\u003cp data-end=\"3917\" data-start=\"3834\"\u003e\u003cstrong data-end=\"3849\" data-start=\"3834\"\u003eMetabolism:\u003c\/strong\u003e Hepatic oxidative and conjugative pathways; high protein binding.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3978\" data-start=\"3918\"\u003e\n\u003cp data-end=\"3978\" data-start=\"3920\"\u003e\u003cstrong data-end=\"3936\" data-start=\"3920\"\u003eElimination:\u003c\/strong\u003e Renal\/hepatic clearance of metabolites.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4088\" data-start=\"3979\"\u003e\n\u003cp data-end=\"4088\" data-start=\"3981\"\u003e\u003cstrong data-end=\"4002\" data-start=\"3981\"\u003eDoping detection:\u003c\/strong\u003e \u003cstrong data-end=\"4028\" data-start=\"4003\"\u003eLong-term metabolites\u003c\/strong\u003e enable detection \u003cstrong data-end=\"4065\" data-start=\"4046\"\u003eweeks after use\u003c\/strong\u003e in anti-doping assays.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"4093\" data-start=\"4090\"\u003e\n\u003ch2 data-end=\"4140\" data-start=\"4095\"\u003e4. Pre-clinical and Translational Evidence\u003c\/h2\u003e\n\u003ch3 data-end=\"4170\" data-start=\"4142\"\u003e4.1 Healthy Volunteers\u003c\/h3\u003e\n\u003cp data-end=\"4410\" data-start=\"4171\"\u003e21-day RCT showed \u003cstrong data-end=\"4233\" data-start=\"4189\"\u003edose-proportional increases in lean mass\u003c\/strong\u003e, small strength\/power improvements, and \u003cstrong data-end=\"4323\" data-start=\"4274\"\u003ereversible suppression of LH\/FSH\/testosterone\u003c\/strong\u003e with \u003cstrong data-end=\"4346\" data-start=\"4329\"\u003eHDL reduction\u003c\/strong\u003e; liver enzymes were largely within reference in the short term.\u003c\/p\u003e\n\u003ch3 data-end=\"4454\" data-start=\"4412\"\u003e4.2 Sarcopenia\/Frailty \u0026amp; Orthopedics\u003c\/h3\u003e\n\u003cp data-end=\"4604\" data-start=\"4455\"\u003eConcept studies target \u003cstrong data-end=\"4494\" data-start=\"4478\"\u003eolder adults\u003c\/strong\u003e and \u003cstrong data-end=\"4516\" data-start=\"4499\"\u003epost-fracture\u003c\/strong\u003e patients to accelerate \u003cstrong data-end=\"4564\" data-start=\"4540\"\u003erehabilitation gains\u003c\/strong\u003e; definitive phase-2\/3 data are lacking.\u003c\/p\u003e\n\u003ch3 data-end=\"4627\" data-start=\"4606\"\u003e4.3 Bone Health\u003c\/h3\u003e\n\u003cp data-end=\"4805\" data-start=\"4628\"\u003eRodent data demonstrate \u003cstrong data-end=\"4677\" data-start=\"4652\"\u003espine\/femur BMD gains\u003c\/strong\u003e and improved \u003cstrong data-end=\"4720\" data-start=\"4691\"\u003ethree-point bend strength\u003c\/strong\u003e, supporting exploration in \u003cstrong data-end=\"4764\" data-start=\"4748\"\u003eosteoporosis\u003c\/strong\u003e or \u003cstrong data-end=\"4804\" data-start=\"4768\"\u003eglucocorticoid-induced bone loss\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cblockquote data-end=\"4975\" data-start=\"4807\"\u003e\n\u003cp data-end=\"4975\" data-start=\"4809\"\u003e\u003cstrong data-end=\"4835\" data-start=\"4809\"\u003eEvidence quality note:\u003c\/strong\u003e Human data remain \u003cstrong data-end=\"4878\" data-start=\"4854\"\u003eshort-term and small\u003c\/strong\u003e. Long-term \u003cstrong data-end=\"4950\" data-start=\"4890\"\u003eefficacy and safety (CV, hepatic, prostate, psychiatric)\u003c\/strong\u003e are \u003cstrong data-end=\"4974\" data-start=\"4955\"\u003enot established\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003chr data-end=\"4980\" data-start=\"4977\"\u003e\n\u003ch2 data-end=\"5015\" data-start=\"4982\"\u003e5. Emerging Clinical Interests\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"5446\" data-start=\"5017\"\u003e\n\u003cthead data-end=\"5055\" data-start=\"5017\"\u003e\n\u003ctr data-end=\"5055\" data-start=\"5017\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"5025\" data-start=\"5017\"\u003eField\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"5037\" data-start=\"5025\"\u003eRationale\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"5055\" data-start=\"5037\"\u003eCurrent status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"5446\" data-start=\"5070\"\u003e\n\u003ctr data-end=\"5167\" data-start=\"5070\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5093\" data-start=\"5070\"\u003e\u003cstrong data-end=\"5092\" data-start=\"5072\"\u003eSarcopenia\/aging\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"5144\" data-start=\"5093\" data-col-size=\"md\"\u003eOral anabolic with less prostate\/steroid baggage\u003c\/td\u003e\n\u003ctd data-end=\"5167\" data-start=\"5144\" data-col-size=\"sm\"\u003eEarly translational\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5259\" data-start=\"5168\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5202\" data-start=\"5168\"\u003e\u003cstrong data-end=\"5201\" data-start=\"5170\"\u003eHip-fracture\/immobilization\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"5241\" data-start=\"5202\" data-col-size=\"md\"\u003eLean-mass restoration to speed rehab\u003c\/td\u003e\n\u003ctd data-end=\"5259\" data-start=\"5241\" data-col-size=\"sm\"\u003ePilot concepts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5360\" data-start=\"5260\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5282\" data-start=\"5260\"\u003e\u003cstrong data-end=\"5281\" data-start=\"5262\"\u003eCancer\/cachexia\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"5332\" data-start=\"5282\" data-col-size=\"md\"\u003eAppetite-neutral anabolic (vs ghrelin mimetics)\u003c\/td\u003e\n\u003ctd data-end=\"5360\" data-start=\"5332\" data-col-size=\"sm\"\u003ePre-clinical\/feasibility\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5446\" data-start=\"5361\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5390\" data-start=\"5361\"\u003e\u003cstrong data-end=\"5389\" data-start=\"5363\"\u003eOsteoporosis (adjunct)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"5430\" data-start=\"5390\" data-col-size=\"md\"\u003eBone-anabolic\/anti-resorptive balance\u003c\/td\u003e\n\u003ctd data-end=\"5446\" data-start=\"5430\" data-col-size=\"sm\"\u003ePre-clinical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"5451\" data-start=\"5448\"\u003e\n\u003ch2 data-end=\"5482\" data-start=\"5453\"\u003e6. Safety and Tolerability\u003c\/h2\u003e\n\u003cul data-end=\"6409\" data-start=\"5484\"\u003e\n\u003cli data-end=\"5662\" data-start=\"5484\"\u003e\n\u003cp data-end=\"5662\" data-start=\"5486\"\u003e\u003cstrong data-end=\"5512\" data-start=\"5486\"\u003eEndocrine suppression:\u003c\/strong\u003e \u003cstrong data-end=\"5578\" data-start=\"5513\"\u003eDose-dependent LH\/FSH and total\/free testosterone suppression\u003c\/strong\u003e within 3 weeks; generally \u003cstrong data-end=\"5619\" data-start=\"5605\"\u003ereversible\u003c\/strong\u003e over several weeks post-discontinuation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5772\" data-start=\"5663\"\u003e\n\u003cp data-end=\"5772\" data-start=\"5665\"\u003e\u003cstrong data-end=\"5676\" data-start=\"5665\"\u003eLipids:\u003c\/strong\u003e \u003cstrong data-end=\"5697\" data-start=\"5677\"\u003eHDL-C reductions\u003c\/strong\u003e (often 10–25%) and occasional \u003cstrong data-end=\"5740\" data-start=\"5728\"\u003e↑ TG\/LDL\u003c\/strong\u003e; monitor cardiovascular risk.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5988\" data-start=\"5773\"\u003e\n\u003cp data-end=\"5988\" data-start=\"5775\"\u003e\u003cstrong data-end=\"5787\" data-start=\"5775\"\u003eHepatic:\u003c\/strong\u003e Short trials showed \u003cstrong data-end=\"5841\" data-start=\"5808\"\u003eminimal median ALT\/AST change\u003c\/strong\u003e, but \u003cstrong data-end=\"5904\" data-start=\"5847\"\u003ecase reports of cholestatic\/drug-induced liver injury\u003c\/strong\u003e exist from real-world\/“supplement” use—source quality and co-ingestants confound.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6080\" data-start=\"5989\"\u003e\n\u003cp data-end=\"6080\" data-start=\"5991\"\u003e\u003cstrong data-end=\"6010\" data-start=\"5991\"\u003eCardiovascular:\u003c\/strong\u003e No outcome data; theoretical risk via \u003cstrong data-end=\"6077\" data-start=\"6049\"\u003eatherogenic lipid shifts\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6158\" data-start=\"6081\"\u003e\n\u003cp data-end=\"6158\" data-start=\"6083\"\u003e\u003cstrong data-end=\"6099\" data-start=\"6083\"\u003eHematologic:\u003c\/strong\u003e Mild \u003cstrong data-end=\"6121\" data-start=\"6105\"\u003e↑ hematocrit\u003c\/strong\u003e possible—monitor if baseline high.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6266\" data-start=\"6159\"\u003e\n\u003cp data-end=\"6266\" data-start=\"6161\"\u003e\u003cstrong data-end=\"6175\" data-start=\"6161\"\u003eOther AEs:\u003c\/strong\u003e Headache, nausea, dry mouth, musculoskeletal aches, insomnia\/irritability in some users.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6409\" data-start=\"6267\"\u003e\n\u003cp data-end=\"6409\" data-start=\"6269\"\u003e\u003cstrong data-end=\"6291\" data-start=\"6269\"\u003eDrug interactions:\u003c\/strong\u003e Potential with drugs affecting hepatic enzymes\/lipids; avoid \u003cstrong data-end=\"6381\" data-start=\"6353\"\u003econcomitant hepatotoxins\u003c\/strong\u003e and \u003cstrong data-end=\"6399\" data-start=\"6386\"\u003epregnancy\u003c\/strong\u003e exposure.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"6440\" data-start=\"6411\"\u003e\u003cstrong data-end=\"6440\" data-start=\"6411\"\u003eComparative safety matrix\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"7062\" data-start=\"6442\"\u003e\n\u003cthead data-end=\"6528\" data-start=\"6442\"\u003e\n\u003ctr data-end=\"6528\" data-start=\"6442\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"6452\" data-start=\"6442\"\u003eConcern\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"6467\" data-start=\"6452\"\u003e\u003cstrong data-end=\"6466\" data-start=\"6454\"\u003eLGD-4033\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"6500\" data-start=\"6467\"\u003e\u003cstrong data-end=\"6499\" data-start=\"6469\"\u003eTestosterone (therapeutic)\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"6528\" data-start=\"6500\"\u003e\u003cstrong data-end=\"6526\" data-start=\"6502\"\u003eEnobosarm (ostarine)\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"7062\" data-start=\"6547\"\u003e\n\u003ctr data-end=\"6627\" data-start=\"6547\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6560\" data-start=\"6547\"\u003eRoute \u0026amp; t½\u003c\/td\u003e\n\u003ctd data-end=\"6580\" data-start=\"6560\" data-col-size=\"sm\"\u003eOral; \u003cstrong data-end=\"6579\" data-start=\"6568\"\u003e24–36 h\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd data-end=\"6610\" data-start=\"6580\" data-col-size=\"sm\"\u003eIM\/SC\/transdermal; variable\u003c\/td\u003e\n\u003ctd data-end=\"6627\" data-start=\"6610\" data-col-size=\"sm\"\u003eOral; 24–36 h\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6739\" data-start=\"6628\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6658\" data-start=\"6628\"\u003eLean-mass gain (short term)\u003c\/td\u003e\n\u003ctd data-end=\"6685\" data-start=\"6658\" data-col-size=\"sm\"\u003e\u003cstrong data-end=\"6684\" data-start=\"6660\"\u003eYes (≈1 kg in 3 wks)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"6708\" data-start=\"6685\" data-col-size=\"sm\"\u003eYes (dose-dependent)\u003c\/td\u003e\n\u003ctd data-end=\"6739\" data-start=\"6708\" data-col-size=\"sm\"\u003eYes (RCTs in illness\/aging)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6811\" data-start=\"6740\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6763\" data-start=\"6740\"\u003eHPG-axis suppression\u003c\/td\u003e\n\u003ctd data-end=\"6778\" data-start=\"6763\" data-col-size=\"sm\"\u003e\u003cstrong data-end=\"6777\" data-start=\"6765\"\u003eModerate\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"6799\" data-start=\"6778\" data-col-size=\"sm\"\u003eMarked (exogenous)\u003c\/td\u003e\n\u003ctd data-end=\"6811\" data-start=\"6799\" data-col-size=\"sm\"\u003eModerate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6871\" data-start=\"6812\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6828\" data-start=\"6812\"\u003eHDL reduction\u003c\/td\u003e\n\u003ctd data-end=\"6841\" data-start=\"6828\" data-col-size=\"sm\"\u003e\u003cstrong data-end=\"6840\" data-start=\"6830\"\u003eCommon\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"6852\" data-start=\"6841\" data-col-size=\"sm\"\u003eVariable\u003c\/td\u003e\n\u003ctd data-end=\"6871\" data-start=\"6852\" data-col-size=\"sm\"\u003eCommon (milder)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6946\" data-start=\"6872\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6887\" data-start=\"6872\"\u003eProstate\/PSA\u003c\/td\u003e\n\u003ctd data-end=\"6911\" data-start=\"6887\" data-col-size=\"sm\"\u003eLow change short-term\u003c\/td\u003e\n\u003ctd data-end=\"6932\" data-start=\"6911\" data-col-size=\"sm\"\u003eIncreases possible\u003c\/td\u003e\n\u003ctd data-end=\"6946\" data-start=\"6932\" data-col-size=\"sm\"\u003eLow change\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7062\" data-start=\"6947\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6971\" data-start=\"6947\"\u003eHepatotoxicity signal\u003c\/td\u003e\n\u003ctd data-end=\"7003\" data-start=\"6971\" data-col-size=\"sm\"\u003e\u003cstrong data-end=\"7002\" data-start=\"6973\"\u003eCase reports (real-world)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"7025\" data-start=\"7003\" data-col-size=\"sm\"\u003eLow (non-17-α oral)\u003c\/td\u003e\n\u003ctd data-end=\"7062\" data-start=\"7025\" data-col-size=\"sm\"\u003eLow–moderate (case reports exist)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"7067\" data-start=\"7064\"\u003e\n\u003ch2 data-end=\"7095\" data-start=\"7069\"\u003e7. Regulatory Landscape\u003c\/h2\u003e\n\u003cul data-end=\"7500\" data-start=\"7097\"\u003e\n\u003cli data-end=\"7149\" data-start=\"7097\"\u003e\n\u003cp data-end=\"7149\" data-start=\"7099\"\u003e\u003cstrong data-end=\"7113\" data-start=\"7099\"\u003eApprovals:\u003c\/strong\u003e \u003cstrong data-end=\"7122\" data-start=\"7114\"\u003eNone\u003c\/strong\u003e (no medical indication).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7269\" data-start=\"7150\"\u003e\n\u003cp data-end=\"7269\" data-start=\"7152\"\u003e\u003cstrong data-end=\"7168\" data-start=\"7152\"\u003eEnforcement:\u003c\/strong\u003e \u003cstrong data-end=\"7185\" data-start=\"7169\"\u003eFDA warnings\u003c\/strong\u003e against SARM-containing “supplements”; multiple \u003cstrong data-end=\"7258\" data-start=\"7234\"\u003eproduct adulteration\u003c\/strong\u003e recalls.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7414\" data-start=\"7270\"\u003e\n\u003cp data-end=\"7414\" data-start=\"7272\"\u003e\u003cstrong data-end=\"7282\" data-start=\"7272\"\u003eSport:\u003c\/strong\u003e \u003cstrong data-end=\"7302\" data-start=\"7283\"\u003eWADA-prohibited\u003c\/strong\u003e (S1 Anabolic Agents). \u003cstrong data-end=\"7343\" data-start=\"7325\"\u003ePositive tests\u003c\/strong\u003e often arise from contaminated supplements; strict liability applies.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7500\" data-start=\"7415\"\u003e\n\u003cp data-end=\"7500\" data-start=\"7417\"\u003e\u003cstrong data-end=\"7442\" data-start=\"7417\"\u003eClinical development:\u003c\/strong\u003e Limited, with no recent pivotal trials publicly reported.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"7505\" data-start=\"7502\"\u003e\n\u003ch2 data-end=\"7530\" data-start=\"7507\"\u003e8. Future Directions\u003c\/h2\u003e\n\u003cul data-end=\"8075\" data-start=\"7532\"\u003e\n\u003cli data-end=\"7636\" data-start=\"7532\"\u003e\n\u003cp data-end=\"7636\" data-start=\"7534\"\u003e\u003cstrong data-end=\"7562\" data-start=\"7534\"\u003eLong-term safety studies\u003c\/strong\u003e (lipids, liver, prostate, mood\/CNS) with standardized, GMP drug supply.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7753\" data-start=\"7637\"\u003e\n\u003cp data-end=\"7753\" data-start=\"7639\"\u003e\u003cstrong data-end=\"7663\" data-start=\"7639\"\u003eElderly\/frailty RCTs\u003c\/strong\u003e pairing LGD-4033 with \u003cstrong data-end=\"7721\" data-start=\"7686\"\u003eprogressive resistance training\u003c\/strong\u003e and \u003cstrong data-end=\"7750\" data-start=\"7726\"\u003eprotein optimization\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7811\" data-start=\"7754\"\u003e\n\u003cp data-end=\"7811\" data-start=\"7756\"\u003e\u003cstrong data-end=\"7779\" data-start=\"7756\"\u003eBone-focused trials\u003c\/strong\u003e (DXA\/BCT, microarchitecture).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7936\" data-start=\"7812\"\u003e\n\u003cp data-end=\"7936\" data-start=\"7814\"\u003e\u003cstrong data-end=\"7837\" data-start=\"7814\"\u003eBiomarker strategy:\u003c\/strong\u003e \u003cstrong data-end=\"7896\" data-start=\"7838\"\u003eIGF-1, myostatin, CK, lipid panel, LH\/FSH\/testosterone\u003c\/strong\u003e, and \u003cstrong data-end=\"7915\" data-start=\"7902\"\u003ectDNA\/PSA\u003c\/strong\u003e where appropriate.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8075\" data-start=\"7937\"\u003e\n\u003cp data-end=\"8075\" data-start=\"7939\"\u003e\u003cstrong data-end=\"7963\" data-start=\"7939\"\u003eMedicinal chemistry:\u003c\/strong\u003e Next-gen SARMs with \u003cstrong data-end=\"8022\" data-start=\"7984\"\u003eimproved anabolic:androgenic ratio\u003c\/strong\u003e, \u003cstrong data-end=\"8044\" data-start=\"8024\"\u003elipid neutrality\u003c\/strong\u003e, and \u003cstrong data-end=\"8074\" data-start=\"8050\"\u003ehepatobiliary safety\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"8080\" data-start=\"8077\"\u003e\n\u003ch3 data-end=\"8105\" data-start=\"8082\"\u003eSelected References\u003c\/h3\u003e\n\u003cul data-end=\"8853\" data-start=\"8107\"\u003e\n\u003cli data-end=\"8250\" data-start=\"8107\"\u003e\n\u003cp data-end=\"8250\" data-start=\"8109\"\u003eBasaria S. et al. \u003cstrong data-end=\"8215\" data-start=\"8127\"\u003eSafety, PK\/PD, and body-composition effects of LGD-4033 in healthy men (21-day RCT).\u003c\/strong\u003e \u003cem data-end=\"8248\" data-start=\"8216\"\u003eJ Gerontol A Biol Sci Med Sci.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8378\" data-start=\"8251\"\u003e\n\u003cp data-end=\"8378\" data-start=\"8253\"\u003eDalton J.T., Kearbey J.D., et al. \u003cstrong data-end=\"8350\" data-start=\"8287\"\u003eNonsteroidal SARMs: pharmacology and therapeutic prospects.\u003c\/strong\u003e \u003cem data-end=\"8376\" data-start=\"8351\"\u003eJ Med Chem; Endocr Rev.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8494\" data-start=\"8379\"\u003e\n\u003cp data-end=\"8494\" data-start=\"8381\"\u003eGao W., et al. \u003cstrong data-end=\"8462\" data-start=\"8396\"\u003eSARMs in muscle and bone—preclinical efficacy and selectivity.\u003c\/strong\u003e \u003cem data-end=\"8492\" data-start=\"8463\"\u003eJ Pharmacol Exp Ther; JBMR.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8616\" data-start=\"8495\"\u003e\n\u003cp data-end=\"8616\" data-start=\"8497\"\u003eEvans N.A., Hasenoehrl T. \u003cstrong data-end=\"8578\" data-start=\"8523\"\u003eAndrogens, erythropoiesis, and cardiovascular risk.\u003c\/strong\u003e \u003cem data-end=\"8614\" data-start=\"8579\"\u003eHematology; Circulation Research.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8722\" data-start=\"8617\"\u003e\n\u003cp data-end=\"8722\" data-start=\"8619\"\u003eDrug Testing \u0026amp; Analysis \/ WADA Lab Reports. \u003cstrong data-end=\"8720\" data-start=\"8663\"\u003eLGD-4033 long-term metabolites and detection windows.\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8853\" data-start=\"8723\"\u003e\n\u003cp data-end=\"8853\" data-start=\"8725\"\u003eCase reports\/series of \u003cstrong data-end=\"8780\" data-start=\"8748\"\u003eSARM-associated liver injury\u003c\/strong\u003e in real-world use. \u003cem data-end=\"8851\" data-start=\"8800\"\u003eHepatology Communications; J Clin Transl Hepatol.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e","brand":"Mijn winkel","offers":[{"title":"Default Title","offer_id":52684861636946,"sku":"10","price":100.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/LGD-4033_Injectable.png?v=1770834912","url":"https:\/\/sciencepeptideslab.com\/products\/injectable-lgd4033-250mg-vial","provider":"Science Peptides Lab","version":"1.0","type":"link"}